Spots Global Cancer Trial Database for ocular melanoma
Every month we try and update this database with for ocular melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Definity for Ultrasound of Intraocular Tumors | NCT01930968 | Ocular Melanoma | 20 Years - | Emory University | ||
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | NCT02858869 | Metastatic Mali... Metastatic Mela... Mucosal Melanom... Ocular Melanoma Stage IV Non-Sm... Stage IV Skin M... Melanoma of Unk... | Pembrolizumab Stereotactic Ra... | 18 Years - | Emory University | |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | NCT05987332 | Metastatic Uvea... | IDE196 Crizotinib Pembrolizumab Ipilimumab Nivolumab Dacarbazine | 18 Years - | IDEAYA Biosciences | |
| SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | NCT01473004 | Stage IV Uveal ... | Sir-Spheres® | 18 Years - | Thomas Jefferson University | |
| THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease | NCT01355120 | Ocular Melanoma | Ipilimumab | 18 Years - | University Hospital, Essen | |
| Prospective Registry of Ocular Melanoma Eye Plaque brachyTherapy Patients | NCT06432660 | Ocular Melanoma | Data collection | 18 Years - | Duke University | |
| Collaborative Ocular Melanoma Study (COMS) | NCT00000124 | Choroid Neoplas... Uveitis | Brachytherapy Eye Removal | 21 Years - | National Eye Institute (NEI) | |
| Study in Subjects With Small Primary Choroidal Melanoma | NCT03052127 | Uveal Melanoma Ocular Melanoma Choroidal Melan... | Light-activated... Laser Activatio... | 18 Years - | Aura Biosciences | |
| Study of Metastatic Ocular Melanoma | NCT00168870 | Ocular Melanoma | Gemcitabine Treosulfan | 18 Years - | Charite University, Berlin, Germany | |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | NCT03070392 | Uveal Melanoma | IMCgp100 Dacarbazine Ipilimumab Pembrolizumab | 18 Years - 99 Years | Immunocore Ltd | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | NCT05524935 | Uveal Melanoma Ocular Melanoma | Pembrolizumab Olaparib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | NCT04417530 | Uveal Melanoma Ocular Melanoma Choroidal Melan... | AU-011 Suprachoroidal ... PDT Laser | 18 Years - | Aura Biosciences | |
| Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate | NCT01046487 | Cancer | Imatinib mesyla... Imatinib mesyla... Imatinib mesyla... Blood sampling | 18 Years - | Centre Oscar Lambret | |
| Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma | NCT05187884 | Ocular Melanoma | Darovasertib | 18 Years - | St Vincent's Hospital, Sydney | |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | NCT05907954 | Uveal Melanoma | Darovasertib | 18 Years - | IDEAYA Biosciences | |
| Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone | NCT00351728 | Ocular Melanoma Choroidal Melan... Uveal Melanoma | 18 Years - | Jonsson Comprehensive Cancer Center | ||
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | NCT01893099 | Ocular Melanoma | Sorafenib Radioembolizati... | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | NCT03070392 | Uveal Melanoma | IMCgp100 Dacarbazine Ipilimumab Pembrolizumab | 18 Years - 99 Years | Immunocore Ltd | |
| Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye | NCT00621439 | Ocular Melanoma | Pegylated Inter... Placebo | 18 Years - | Emory University | |
| SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | NCT01473004 | Stage IV Uveal ... | Sir-Spheres® | 18 Years - | Thomas Jefferson University | |
| Study in Subjects With Small Primary Choroidal Melanoma | NCT03052127 | Uveal Melanoma Ocular Melanoma Choroidal Melan... | Light-activated... Laser Activatio... | 18 Years - | Aura Biosciences | |
| SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | NCT01473004 | Stage IV Uveal ... | Sir-Spheres® | 18 Years - | Thomas Jefferson University | |
| A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma | NCT00062933 | Melanoma | Laparotomy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy | NCT00346372 | Ocular Melanoma | 18 Years - | Jonsson Comprehensive Cancer Center | ||
| Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma | NCT00109005 | Melanoma | Revlimid | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | NCT02315066 | Neoplasms | PF-04518600 PF-04518600 PF-04518600 plu... PF-04518600 plu... | 18 Years - | Pfizer | |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | NCT01728051 | Metastatic Live... Ocular Melanoma Cutaneous Melan... | Melphalan Percutaneous He... | 18 Years - | Delcath Systems Inc. | |
| SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | NCT01473004 | Stage IV Uveal ... | Sir-Spheres® | 18 Years - | Thomas Jefferson University | |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | NCT05907954 | Uveal Melanoma | Darovasertib | 18 Years - | IDEAYA Biosciences | |
| Cytogenetic Study of Ocular Melanoma | NCT00344799 | Choroidal Melan... | 18 Years - | Jonsson Comprehensive Cancer Center | ||
| Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma | NCT03172299 | Ocular Melanoma | Aflibercept Inj... False injection | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | NCT05524935 | Uveal Melanoma Ocular Melanoma | Pembrolizumab Olaparib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy | NCT00346372 | Ocular Melanoma | 18 Years - | Jonsson Comprehensive Cancer Center | ||
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | NCT03947385 | Metastatic Uvea... Cutaneous Melan... Colorectal Canc... Other Solid Tum... | IDE196 Binimetinib Crizotinib | 18 Years - | IDEAYA Biosciences | |
| Definity for Ultrasound of Intraocular Tumors | NCT01930968 | Ocular Melanoma | 20 Years - | Emory University | ||
| A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | NCT05576077 | Breast Cancer Colorectal Canc... Uveal Melanoma Cutaneous Melan... Non-Small Cell ... Head and Neck S... | TBio-4101 Pembrolizumab | 18 Years - 70 Years | Turnstone Biologics, Corp. | |
| A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp | NCT04960891 | Uveal Melanoma | Tebentafusp | 18 Years - | Immunocore Ltd | |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | NCT01728051 | Metastatic Live... Ocular Melanoma Cutaneous Melan... | Melphalan Percutaneous He... | 18 Years - | Delcath Systems Inc. | |
| A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma | NCT00062933 | Melanoma | Laparotomy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye | NCT00621439 | Ocular Melanoma | Pegylated Inter... Placebo | 18 Years - | Emory University | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | NCT05628883 | Metastatic Mela... Unresectable Me... Acral Melanoma Mucosal Melanom... Cutaneous Melan... Ocular Melanoma Uveal Melanoma Iris Melanoma Conjunctival Me... Non-Cutaneous M... | TBio-4101 Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
| Study of Metastatic Ocular Melanoma | NCT00168870 | Ocular Melanoma | Gemcitabine Treosulfan | 18 Years - | Charite University, Berlin, Germany | |
| Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | NCT05524935 | Uveal Melanoma Ocular Melanoma | Pembrolizumab Olaparib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
